Evaluating the potential impact of targeted vaccination strategies against severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) outbreaks in the healthcare setting

Table 2 Proportion of cases averted by each targeted vaccination strategies in each MERS and SAR healthcare setting outbreak

Outbreak	Vaccinated Population	Proportion Vaccinated	Proportion of Cases Averted (95% CI)
Singapore (SARS)	HCW	0.50	0.22 (0.14–0.30)
Singapore (SARS)	HCW	0.75	0.36 (0.26–0.45)
Singapore (SARS)	HCW	1.00	0.89 (0.83–0.95)
South Korea (MERS)	HCW	0.50	0.06 (0.01–0.11)
South Korea (MERS)	HCW	0.75	0.10 (0.04–0.16)
South Korea (MERS)	HCW	1.00	0.13 (0.06–0.19)
Toronto (SARS)	HCW	0.50	0.18 (0.10–0.25)
Toronto (SARS)	HCW	0.75	0.27 (0.18–0.36)
Toronto (SARS)	HCW	1.00	0.39 (0.29–0.48)
Singapore (SARS)	Patients	0.50	0.43 (0.34–0.53)
Singapore (SARS)	Patients	0.75	0.57 (0.47–0.67)
Singapore (SARS)	Patients	1.00	0.71 (0.62–0.80)
South Korea (MERS)	Patients	0.50	0.59 (0.49–0.69)
South Korea (MERS)	Patients	0.75	0.76 (0.67–0.84)
South Korea (MERS)	Patients	1.00	0.87 (0.80–0.93)
Toronto (SARS)	Patients	0.50	0.47 (0.37–0.57)
Toronto (SARS)	Patients	0.75	0.67 (0.57–0.76)
Toronto (SARS)	Patients	1.00	0.89 (0.83–0.95)

ISSN: 1742-4682